NBT Bank N A NY Sells 3,984 Shares of Johnson & Johnson $JNJ

NBT Bank N A NY lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 3.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 108,777 shares of the company’s stock after selling 3,984 shares during the quarter. Johnson & Johnson comprises 1.5% of NBT Bank N A NY’s portfolio, making the stock its 12th largest position. NBT Bank N A NY’s holdings in Johnson & Johnson were worth $20,590,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares during the last quarter. Norges Bank bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $4,877,174,000. Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after buying an additional 620,039 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 0.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after buying an additional 52,074 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Morgan Stanley lifted their price objective on Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Finally, Scotiabank began coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 target price for the company. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $218.81 on Tuesday. The stock has a market capitalization of $527.18 billion, a P/E ratio of 21.12, a PEG ratio of 2.25 and a beta of 0.34. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $220.11. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $206.43 and a two-hundred day simple moving average of $187.62.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer publicly praised J&J, highlighting its diversified businesses and steady cash flows — a high‑profile endorsement that can attract retail flows and support the stock. Jim Cramer Just Can’t Stop Praising Johnson & Johnson (JNJ)
• Positive Sentiment: J&J is featured in dividend-focused lists as a reliable income name, reinforcing demand from income investors given its yield and long dividend history. 3 Dividend Stocks to Own No Matter Where the Market Moves in 2026
• Positive Sentiment: Zacks highlighted J&J in its investment ideas feature, keeping the stock on investors’ radar as a large-cap healthcare pick. Zacks Investment Ideas feature highlights: Netflix, Intel and Johnson & Johnson
• Neutral Sentiment: Benzinga flags a “$10 billion test” in J&J’s 2026 outlook — management’s guidance and 2026 execution will be pivotal in the Q4 print and could swing sentiment either way. Johnson & Johnson’s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4
• Neutral Sentiment: Analyst previews (Zacks, TipRanks, others) show mixed views: strong pharma and MedTech momentum but pressure from Stelara biosimilar competition and China headwinds — earnings will clarify the balance. Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
• Neutral Sentiment: Pre‑earnings pieces (TipRanks/MarketBeat) note analysts expect modest revenue growth into Q4; some investors are using hedged exposure strategies ahead of the release to limit risk. Is Johnson & Johnson (JNJ) Stock a Buy Ahead of Q4 Earnings?
• Negative Sentiment: Seeking Alpha warns that a sizable 2025 downgrade has tempered expectations; lowered growth assumptions can keep a lid on valuation and increase downside risk if guidance disappoints. Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)
• Negative Sentiment: Bank of America reiterated a Hold rating, signaling limited near‑term upside in analysts’ view and potentially constraining momentum from bullish headlines. Bank of America Securities Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.